Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report

[1] Oberg K(2005)Endocrine tumours of the pancreas Best Pract Res Clin Gastroenterol 19 753-781

[2] Eriksson B(2000)Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190 432-445

[3] Chamberlain RS(2011)Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression J Clin Oncol 29 2372-2377

[4] Canes D(2006)An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors Ann Surg 244 845-851

[5] Brown KT(1993)Nonfunctioning islet cell carcinoma of the pancreas Surgery 114 1175-1181

[6] Saltz L(2001)Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients Surgery 130 1078-1085

[7] Jarnagin W(2023)Peptide receptor radionuclide therapy (PRRT): innovations and improvements Cancers 26 2124-2130

[8] Fong Y(2008)Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 55 183-190

[9] Panzuto F(2014)Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate J Nucl Med 23 4617-4624

[10] Boninsegna L(2017)Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors Clin Cancer Res 376 125-135

[1] Oberg K(2005)Endocrine tumours of the pancreas Best Pract Res Clin Gastroenterol 19 753-781

[2] Eriksson B(2000)Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190 432-445

[3] Chamberlain RS(2011)Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression J Clin Oncol 29 2372-2377

[4] Canes D(2006)An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors Ann Surg 244 845-851

[5] Brown KT(1993)Nonfunctioning islet cell carcinoma of the pancreas Surgery 114 1175-1181

[6] Saltz L(2001)Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients Surgery 130 1078-1085

[7] Jarnagin W(2023)Peptide receptor radionuclide therapy (PRRT): innovations and improvements Cancers 26 2124-2130

[8] Fong Y(2008)Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 55 183-190

[9] Panzuto F(2014)Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate J Nucl Med 23 4617-4624

[10] Boninsegna L(2017)Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors Clin Cancer Res 376 125-135